Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | -898,000 | -523,000 | 83,000 | 1,610,000 | 152,000 |
| Other Working Capital | -346,000 | -639,000 | -50,000 | 926,000 | -49,000 |
| Other Operating Activity | 4,213,000 | 3,780,000 | 3,545,000 | 1,609,000 | 3,221,000 |
| Operating Cash Flow | $2,969,000 | $2,618,000 | $3,578,000 | $4,145,000 | $3,324,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -942,000 | -1,031,000 | -1,243,000 | -1,364,000 | -1,281,000 |
| Net Acquisitions | -783,000 | -536,000 | -1,960,000 | -2,898,000 | -3,070,000 |
| Purchase Of Investment | -13,000 | -102,000 | -441,000 | -396,000 | -57,000 |
| Sale Of Investment | 212,000 | 429,000 | 70,000 | 3,000 | 376,000 |
| Purchase Sale Intangibles | 595,000 | 2,010,000 | 1,082,000 | 559,000 | -330,000 |
| Other Investing Activity | 2,350,000 | 2,531,000 | 1,540,000 | 1,554,000 | 1,253,000 |
| Investing Cash Flow | $-657,000 | $963,000 | $-2,328,000 | $-3,969,000 | $-4,239,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -516,000 | -98,000 | 336,000 | -303,000 | -630,000 |
| Debt Issued | 500,000 | 2,971,000 | 1,988,000 | 2,491,000 | 5,928,000 |
| Debt Repayment | -1,500,000 | -1,400,000 | -1,750,000 | 0 | -884,000 |
| Common Stock Issued | 3,525,000 | 34,000 | 43,000 | 47,000 | 43,000 |
| Dividend Paid | -3,592,000 | -3,484,000 | -3,519,000 | -3,561,000 | -3,486,000 |
| Other Financing Activity | -182,000 | -67,000 | -34,000 | 2,000 | -93,000 |
| Financing Cash Flow | $-1,765,000 | $-2,044,000 | $-2,936,000 | $-1,324,000 | $878,000 |
| Exchange Rate Effect | 5,000 | -38,000 | -66,000 | 21,000 | -76,000 |
| Beginning Cash Position | 4,671,000 | 3,172,000 | 4,924,000 | 6,051,000 | 6,164,000 |
| End Cash Position | 5,223,000 | 4,671,000 | 3,172,000 | 4,924,000 | 6,051,000 |
| Net Cash Flow | $547,000 | $1,537,000 | $-1,686,000 | $-1,148,000 | $-37,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,969,000 | 2,618,000 | 3,578,000 | 4,145,000 | 3,324,000 |
| Capital Expenditure | -2,460,000 | -1,371,000 | -1,620,000 | -2,314,000 | -2,788,000 |
| Free Cash Flow | 509,000 | 1,247,000 | 1,958,000 | 1,831,000 | 536,000 |